Table 3.
Incremental costs and effects for genotypes 1–3
| Strategy | QALYs | Costs (€) | IE compared with current | IC compared with current | ICER vs. currenta | ICER vs. cost-effective aboveb | NHB | INHB vs. current |
|---|---|---|---|---|---|---|---|---|
| Gentoype 1 | ||||||||
| Currenta | 409,979 | 794,866,877 | 398,619 | |||||
| PAR/RIT12 + OMB12 + DAS12 | 412,402 | 861,092,154 | 2423 | 66,225,277 | 27,336 | 27,336 | 400,095 | 1476 |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | 412,454 | 869,063,952 | 2475 | 74,197,075 | 29,983 | 153,304 | 400,033 | 1414 |
| SIM12 + PR24–48 RGT | 411,958 | 983,161,610 | 1979 | 188,294,733 | 95,166 | Dominated | 397,906 | − 713 |
| SOF12 + PR12 | 412,226 | 1,030,910,982 | 2247 | 236,044,104 | 105,053 | Dominated | 397,492 | − 1127 |
| SOF12 + LDV12 | 412,496 | 1,045,826,830 | 2517 | 250,959,953 | 99,718 | 1,963,174 | 397,549 | − 1070 |
| DCV12 + SOF12 | 412,361 | 1,208,366,307 | 2382 | 413,499,429 | 173,593 | Dominated | 395,091 | − 3528 |
| SIM12 + SOF12 | 412,317 | 1,224,266,148 | 2338 | 429,399,271 | 183,700 | Dominated | 394,819 | − 3800 |
| SOF24 + RBV24 | 412,067 | 1,345,247,080 | 2088 | 550,380,203 | 263,592 | Dominated | 392,841 | − 5778 |
| Genotype 2 | ||||||||
| Currentc | 411,026 | 744,580,931 | 400,384 | |||||
| SOF12 + RBV12 | 414,739 | 957,862,912 | 3713 | 213,281,981 | 57,447 | 57,447 | 401,049 | 664 |
| SOF12 + PR12 | 414,729 | 977,104,159 | 3703 | 232,523,228 | 62,792 | Dominated | 400,764 | 380 |
| Genotype 3 | ||||||||
| Currenta | 411,900 | 734,152,846 | 401,407 | |||||
| SOF12 + PR12 | 415,749 | 968,722,985 | 3849 | 234,570,139 | 60,943 | 60,943 | 401,904 | 496 |
| DCV12 + SOF12 | 415,776 | 1,147,061,915 | 3876 | 412,909,069 | 106,532 | 6,629,700 | 399,382 | − 2025 |
| SOF24 + RBV24 | 415,710 | 1,283,054,956 | 3810 | 548,902,109 | 144,069 | Dominated | 397,372 | − 4035 |
DAS dasabuvir, DCV daclatasvir, € Euros, IC incremental costs, expressed in €, ICER incremental cost-effectiveness ratio (€/QALY), IE incremental effect, expressed in QALYs, INHB incremental net health benefit, LDV ledipasvir, NHB net health benefit, calculated with a cost-effectiveness threshold of €70,000 per QALY, OMB ombitasvir, PAR paritaprevir, PR pegylated interferon-α-2a and ribavirin, QALYs quality-adjusted life-years, RBV ribavirin, RGT response-guided therapy, RIT ritonavir, SIM simeprevir, SOF sofosbuvir
aCurrent is defined as PR48 for genotypes 1 and 3
bStrategies sorted according to increasing cost and compared with the strategy above that is considered cost effective
cCurrent is defined as PR24 for genotype 2